Research Article| Volume 161, ISSUE 3, P676-680, June 2021

Download started.


Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer


      • Limited treatment options exist for homologous recombination proficient ovarian cancer.
      • Vigil is an anticancer immuno-therapeutic.
      • Vigil provides neoantigen education, GMCSF activation and TGFβ suppression reversal.
      • Vigil vs. placebo shows benefit of RFS and OS (HR = 0.386, p = 0.007; HR = 0.342, p = 0.019).
      • Vigil demonstrated no Grade 3/4 toxicity compared to placebo.



      Recently, Vigil showed significant clinical benefit with improvement in relapse free (RFS) and overall survival (OS) in pre-planned subgroup analysis in stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) molecular profile. Here we analyze homologous recombination (HR) status of patients enrolled in the Phase 2b VITAL study and determine clinical benefit of Vigil in HR proficient (P) patients.


      Patients were previously enrolled in a Phase 2b, double-blind, placebo-controlled trial. All were in complete response with Stage III/IV high grade serious, endometroid or clear cell ovarian cancer. HR status was determined using MyChoice®CDx score (<42 = HRP) (Myriad Genetics, Inc., UT). Post-hoc analyses were carried out using Kaplan Meier and restricted mean survival time (RMST) analysis to evaluate RFS and OS based on HR deficiency (D) status.


      RFS was improved with Vigil (n = 25) in HRP patients compared to placebo (n = 20) (HR = 0.386; 90% CI 0.199–0.750; p = 0.007), results were verified by RMST (p = 0.017). Similarly, OS benefit was observed in Vigil group compared to placebo (HR = 0.342; 90% CI 0.141–0.832; p = 0.019). Results with OS were also verified with RMST (p = 0.008).


      Vigil exhibited clinical benefit in HRP molecular profile patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Xu K.
        • Yang S.
        • Zhao Y.
        Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
        Oncotarget. 2017; 8: 285-302
        • Keyvani V.
        • et al.
        Ovarian cancer stem cells and targeted therapy.
        J. Ovarian Res. 2019; 12: 120
        • Morand S.
        • et al.
        BRCA1/2 mutation status impact on autophagy and immune response: unheralded target.
        JNCI Cancer Spectrum. 2020; 4
        • Gonzalez-Martin A.
        • et al.
        Niraparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2391-2402
        • Tewari K.S.
        • et al.
        Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.
        J. Clin. Oncol. 2019; 37: 2317-2328
        • Oh J.
        • et al.
        Phase II study of vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
        Gynecol. Oncol. 2016; 143: 504-510
        • Maples P.
        • et al.
        FANG vaccine: autologous tumor cell vaccine genetically modified to express GM-CSF and block production of Furin.
        Bioprocess. J. 2010; 8: 4-14
        • Senzer N.
        • et al.
        Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer.
        Mol. Ther. 2012; 20: 679-686
        • Senzer N.
        • et al.
        Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANGTM) in advanced Cancer.
        J. Vacc. Vaccin. 2013; 4: 209
        • Rocconi R.P.
        • et al.
        Gemogenovatucel-T (vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
        Lancet Oncol. 2020; 21: 1661-1672
        • Moore K.
        • et al.
        Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2018; 379: 2495-2505
        • Ray-Coquard I.
        • et al.
        Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2416-2428
        • McGranahan N.
        • et al.
        Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
        Science. 2016; 351: 1463-1469
        • Oh J.
        • et al.
        Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
        Gynecol. Oncol. Rep. 2020; 34: 100648
        • Herron J.
        • et al.
        Vigil: personalized immunotherapy generating systemic cytotoxic T cell response.
        Cancer Sci. Res. 2020; 3: 1-4
        • Craig D.J.
        • et al.
        Resident Memory T cells and their effect on cancer.
        Vaccines (Basel). 2020; 8
        • Devanaboyina M.
        • et al.
        Immune response role of angiogenesis inhibitors.
        Clin. Oncol. Res. 2021; 4: 4-13

      Linked Article